Skip to main content

REVIEW article

Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1446468
This article is part of the Research Topic Immunity, Atherosclerosis and Cardiovascular Disease: An Interdisciplinary Approach to Cardiometabolic Health View all 3 articles

Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: A Comprehensive Review

Provisionally accepted
Alicja Skrobucha Alicja Skrobucha *Patryk Pindlowski Patryk Pindlowski Natalia Krajewska Natalia Krajewska Marcin Grabowski Marcin Grabowski Szymon Jonik Szymon Jonik
  • 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

The final, formatted version of the article will be published soon.

    Coronary artery disease (CAD) -cardiovascular condition occuring due to atherosclerotic plaque accumulation in the epicardial arteries -is responsible for disabilities of millions of people worldwide and remains the most common single cause of death. Inflammation is the primary pathological Formatted: Polish mechanism underlying CAD, since is involved in atherosclerotic plaque formation. Glucagon-like peptide-1 (GLP-1) is a peptide hormone which role extends beyond well-known carbohydrates metabolism. In in vitro studies GLP-1 receptor agonism is associated with regulation of several inflammatory pathways, including cytokine production, lypotoxicity and macrophages differentiation.In this review, we aimed to provide a comprehensive summary of the potential relationship between anti-inflammatory effects of GLP-1 and CAD.We have described a well-established association of anti-inflammatory properties of GLP-1 and atherosclerosis in animals. Pre-clinical studies showed that anti-atherogenic effect of GLP-1 is independent of modulation of plasma lipid levels and depends on anti-inflammatory response.Human studies in this area are limited by small sample size and often nonrandomized character.However, beneficial impact of GLP-1 on endothelial function and microcirculatory integrity in patients with CAD have been described.Understanding atherosclerosis as a chronic inflammatory disease offers new opportunities for the prevention and treatment of CAD. Therefore, we emphasize the need for larger randomized controlled trials focusing on cardiovascular morbidity and mortality to verify the cardioprotective properties of GLP-1R agonists in patients with CAD.

    Keywords: anti-inflammatory, Atherosclerosis, Coronary Artery Disease, Glucagon-like pep tide 1, mechanisms

    Received: 09 Jun 2024; Accepted: 21 Nov 2024.

    Copyright: © 2024 Skrobucha, Pindlowski, Krajewska, Grabowski and Jonik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Alicja Skrobucha, 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.